Results 51 to 60 of about 219,068 (308)

TRMT6‐Mediated m1A Modification of CDK9 mRNA Is a Dual‐Pronged Pathogenic Driver for HBV‐Related Hepatocellular Carcinoma

Advanced Science, EarlyView.
TRMT6‐mediated m1A modification in CDK9 mRNA enhances its mRNA stability and translation efficiency, thereby increasing the protein levels of CDK9. Upregulated CDK9 promotes the progression of HCC by elevating the levels of oncogenic factors including p‐STAT3, MCL1, and BCL‐2. On the other hand, CDK9 phosphorylates TARDBP at Ser254 to activate HBV core
Rui Zhang, Dandan Zong, Rui Liu, Yubo Wang, Qingqing Gu, Yao Yao, Wenfang Zheng, Mengmeng Yuan, Simeng Wang, Rongrong Cui, Daxu Li, Siwen Dang, Peng Hou   +12 more
wiley   +1 more source

A Single-Step Immunocapture Assay to Quantify HCC Exosomes Using the Highly Sensitive Fluorescence Nanoparticle-Tracking Analysis

Journal of Hepatocellular Carcinoma, 2023
Ali Riza Koksal,1 Nergiz Ekmen,2 Yucel Aydin,2 Kelley Nunez,3 Tyler Sandow,4 Molly Delk,2 Martin Moehlen,2 Paul Thevenot,3 Ari Cohen,3,5 Srikanta Dash1,2,6 1Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New ...
Koksal AR, Ekmen N, Aydin Y, Nunez K, Sandow T, Delk M, Moehlen M, Thevenot P, Cohen A, Dash S   +9 more
doaj  

Cip2a Mediates Effects of Bortezomib on Phospho-Akt and Apoptosis in Hepatocellular Carcinoma Cells

, 2011
Previously, we reported that Akt inactivation determines the sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. In this study, we report that cancerous inhibitor of protein phosphatase 2A (CIP2A), a cellular inhibitor of protein ...
陳昆鋒;林育靖;陳培哲;鄭安理, Chen, K-F; Liu, C-Y; Lin, Y-C; Yu, H-C; Liu, T-H; Hou, D-R; Chen, P-J; Cheng, A-L   +1 more
core   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

Advanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong, Yuhang Xie, Zhijie Weng, Yongzhi Wu, Longjiang Li, Bo Li   +5 more
wiley   +1 more source

Preliminary results of retrospective analysis Atezolizumab and Bevacizumab in first-line therapy of advanced HCC

Медицинский совет, 2021
Introduction. HCC is a challenge for clinical oncology. 1-year mortality for advanced HCC accounts for 66% in theRussian Federation. The results obtained in the combined Atezolizumab and Bevacizumab therapy in the advanced HCC cases are reported ...
I. А. Dzhanyan, М. V. Natrusova, V. V. Breder   +2 more
doaj   +1 more source

Serum Exosome-Derived piRNAs Could Be Promising Biomarkers for HCC Diagnosis

, 2023
Tao Rui,1,2 Kai Wang,1,2 Aizhai Xiang,1 Jufeng Guo,1 Ning Tang,1 Xin Jin,1 Yimou Lin,3 Jian Liu,1 Xiaobing Zhang1,2 1Department of Surgery, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s ...
Rui T, Xiang A, Liu J, Jin X, Guo J, Tang N, Zhang X, Lin Y, Wang K   +8 more
core  

apyrros/HCC-comorbidities: HCC comorbidity predictor

, 2022
V 1.0 for ...
apyrros
core   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. [PDF]

, 2012
HCC is diagnosed in approximately half a million people per year, worldwide. Staging is a more complex issue than in most other cancer entities and, mainly due to unique geographic characteristics of the disease, no universally accepted staging system ...
Straub, Gundula, Rolf Lamerz (128813), Göke, Burkhard, Christoph J Zech, Thomas Nickel (128829), Markus Rentsch (128832), Frank T Kolligs, Dorothea Nagel, Christoph J. Zech (128818), Sappl, Julia, Markus Rentsch, Burkhard Göke (109829), Mark op den Winkel, Petra Stieber (65225), Nagel, Dorothea, Petra Stieber, Burkhard Göke, Thomas Nickel, Mark op den Winkel (128802), Dorothea Nagel (65229), Gundula Straub, Lamerz, Rolf, Julia Sappl, Stieber, Petra, Kolligs, Frank T., Rentsch, Markus, Rolf Lamerz, Nickel, Thomas, Winkel, Philip op den, Julia Sappl (128805), Frank T. Kolligs (128835), Philip op den Winkel, Philip op den Winkel (128808), Gundula Straub (128821), Winkel, Mark op den, Zech, Christoph J.   +35 more
core   +1 more source

Combination Immunotherapy as a Promising Strategy to Overcome Immunotherapy Resistance: From Emergence to Next‐Generation Approaches

Advanced Science, EarlyView.
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey, Sudhir Kumar Rai, Li Ma, Lauren Higa, Vedbar Khadka, Hua Yang, Youping Deng   +6 more
wiley   +1 more source